TrakCel appoints Chief Product Officer to accelerate growth

TrakCel appoints Chief Product Officer to accelerate growth



New role will focus on the development and provision of TrakCel’s products and services

Cardiff, UK, January 16, 2020 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, announces today the appointment of Debra Susarchick as Chief Product Officer.

Debra Susarchick is TrakCel’s latest senior appointment as the company expands and focuses on growth and product management. TrakCel is looking to continue to innovate and improve efficiencies within the industry. It is therefore leading by example through its investment in developing and improving its own products and services.

“TrakCel’s software orchestration platforms are already established, in terms of primary provision to international clinical development of the cell and gene therapy industry. The next step in TrakCel’s pursuit of growth, and supporting the industry in creating commercially viable cell and gene therapies, is to further extend, develop and tailor its products in line with the sectors fast growing market needs,” said Ravi Nalliah, CEO, TrakCel. “We selected Debra Susarchick for her first-hand commercial experience, especially leading the roll out of Kite Konnect™ in 21 countries, as well as clinical tenure from her positions at Celgene and Merck. In the role of Chief Product Officer, Debra will make a significant contribution towards the clinical and commercial requirements of our customers.”


I hope to make a significant contribution – with a key focus on the requirements for commercialization and standardization within the sector


Debra brings to TrakCel over 22 years of experience within the pharmaceutical industry and 11 within oncology and cell therapy. In particular, Debra’s experience, as Senior Director of Cell Therapy Business Optimization at Kite Pharma saw her direct the design, development and global launch of the Kite Konnect™ customer engagement platform, which supported the launch of Yescarta®, the first autologous CAR-T therapy for adult Large B Cell Lymphoma. Debra was involved in solving linguistic, cultural, regulatory, financial, IT, clinical and legal requirements for the product. Her key focus was in customer service, where she harnessed her industry knowledge and partnerships. This will be essential for her work with TrakCel. Furthermore, her role at Kite role enabled her to gather a considerable amount of clinical experience, working on the ground in with US and international hospitals.

Debra additionally acquired extensive clinical and commercial experience in her position as Senior Director of Commercial Operations at Celgene, where she directed the implementation of large transformation and enablement programs in support of Celgene’s Hematology/Oncology franchise. As a result of this acquired experience, Debra brings additional industry insight to TrakCel in bridging the clinical and commercial gap for clients.

Serving 12 years at Merck, as the Manager of Human Health client services, Debra developed exemplary client relationships through the account management of a $13 million project portfolio in support of the global sales & marketing organization. These skills will be an integral part of her new role at TrakCel.

“The cell and gene therapy industry is expanding and TrakCel is growing with the industry. When a company grows, it needs to make ongoing changes to develop. I hope to make a significant contribution to that change – with a key focus on the requirements for commercialization and standardization within the sector,” said Debra Susarchick, Chief Product Officer, TrakCel. “I am very excited to engage with TrakCel’s current and prospective customers, understand their unique business requirements and then partner with our very competent technology team to build out additional components and functionality that will continue to position TrakCel’s products as the premier selling cell therapy orchestration platform available.”



About TrakCel

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.  TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.

Debra Susarchick - Chief PRoduct Officer, TrakCel


Debra Susarchick
Chief Product Officer
TrakCel

TrakCel announces strategic partnership with WuXi AppTec Advanced Therapies for optimization of supply chain for cell and gene therapy treatments

Partnership combines global CDMO services with industry leading cellular orchestration platform

Cardiff, UK & Philadelphia, PA, October 1, 2019 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems and WuXi AppTec Advanced Therapies, a Contract Development and Manufacturing Organization (CDMO), today announce a collaborative agreement designed to accelerate the seamless delivery of advanced therapy treatments to bring an end-to-end solution to mutual customers.

To provide full visibility and control of their collection-to-administration supply chain, cell therapy companies need to ensure consistent product handling and data capture across all supply chain partners. This is increasingly being achieved through the deployment of supply chain management software, such as TrakCel’s platform. Challenges can arise if software-driven workflows do not account for established processes in place at each supply chain partner. For example, if a contract manufacturer needs to change their processes to fit in with those designed into supply chain management software, this can increase costs and timelines for software adoption. Conversely, rewriting software after it becomes apparent that it will not work for a contract manufacturer also incurs additional expense and can delay software deployment.

TrakCel and WuXi AppTec Advanced Therapies will leverage configured manufacturing module in TrakCel’s software, based around WuXi’s current standard operating procedures and preferred workflows. The design of this module will be based on the companies’ long and extensive working relationship. WuXi AppTec Advanced Therapies was the first CDMO to use TrakCel’s software and its Philadelphia, PA site currently has a greater number of users than any other facility in the supply chain. The resultant pre-built manufacturing module in the TrakCel platform will shorten the time and costs associated with deploying an end-to-end solution to TrakCel and WuXi’s mutual clients.

Both WuXi AppTec Advanced Therapies and TrakCel will continue to build from their long extensive partnership by exploring opportunities to further enhance their combined service to their mutual customers. As one example, automated population of TrakCel’s scheduling system with data from WuXi’s own manufacturing capacity plans will further strengthen the ability of existing clients of both companies to accurately plan patient treatment schedules. By increasing the ability to maximize the utilization of contracted manufacturing resources, this should have a considerable impact on cost of goods to patients and healthcare providers.

“As one of the first CDMOs to use TrakCel’s software and the supply chain partner with more users than any other facility, WuXi AppTec Advanced Therapies is well placed to collaborate with TrakCel to identify a more efficient way of working together. It is the latest development in TrakCel’s formation of an international partner ecosystem of connected and complementary cell and gene therapy service providers. This partner ecosystem as a result now includes a commercial scale, third party manufacturing company,” said Ravi Nalliah, CEO, TrakCel. “The TrakCel partnership with WuXi AppTec Advanced Therapies will enable both companies to move towards increased standardization and improved delivery of these innovative treatments to patients around the world.”

“We are pleased to establish a collaborative agreement with TrakCel to support customers that seek to promote streamlining personalized therapies from specimen connections to manufacturing,” said Felix Hsu, Senior Vice President and Global Head of WuXi AppTec Advanced Therapies. “With our leading integrated manufacturing and testing services, we believe we can bring even more speed, reliability and security to an already complex manufacturing and supply chain. We are committed to helping our partners deliver more innovative therapies to patients and the market sooner.”

About TrakCel

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.

TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.

Please visit: https://trakcel.com

About WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,600 collaborators from over 30 countries to improve the health of those in need – and to fulfill our dream that “every drug can be made and every disease can be treated.”

Please visit: http://www.wuxiapptec.com

About WuXi Advanced Therapies (WuXi ATU)

The advanced therapies business unit of WuXi AppTec is a Contract Development and Manufacturing Organization (CDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability.

Please visit www.advancedtherapies.com.

Media Contact:

 

Neil Hunter / Michelle Boxall
Image Box PR
neil@imageboxpr.co.uk / michelle@imageboxpr.co.uk
Tel +44 20 8943 4685

or

Min Park
Sr. Director, Marketing
WuXi AppTec Advanced Therapies
min.park@wuxiapptec.com

McKesson and TrakCel Launch Innovative Collaboration to Support Commercialization of Cell and Gene Therapies

Goal is to increase access to complex medications to ensure patients get the right drug at the right time faster

IRVING, Texas, US and CARDIFF, UK, Sept. 11, 2019McKesson, a leading provider of third-party logistic (3PL) services, patient access support and specialty pharmacy solutions, and TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, today announce a collaboration to support cell and gene therapy late-stage developers. The collaboration will integrate both companies’ supply chain tracking and patient access services to enable a more efficient path for the industry to develop the next-generation of commercial therapies.

Combining TrakCel’s data tracking and personalized medicine orchestration software system with McKesson’s existing high-touch patient platform, as well as both companies’ expertise and support, will provide an end-to-end solution for the cell and gene therapy industry to manage the entire therapeutic supply chain. McKesson and TrakCel will begin by developing an initial solution design. The combined solutions will then be offered to individual clients that would specifically benefit from this combination.

The blend of these product suites is specifically designed for the increasing number of developers approaching the commercial launch of cell and gene therapies. The integrated platform enables the scale-up of products towards market delivery. This includes automatic scheduling of product-specific workflows across multiple supply chain partners and care team members, and validated chain-of-identity tracking to guarantee correct drug product delivery. These capabilities ensure that the patient receives the correct, uncompromised treatment at the right time.

“TrakCel and McKesson have committed to working closely with a variety of current and future clients to specifically develop tailor-made solutions,” said Ravi Nalliah, CEO of TrakCel. “This integration of solutions and expertise with McKesson will enable us to continue to meet the needs of the cell and gene therapy sector and patients as more products move towards commercialization.”

“Precision medicine and the delivery of innovative cell and gene therapies require a personalized approach,” said Layne Martin, VP/GM, Specialty Distribution Solutions, McKesson Life Sciences. “TrakCel’s robust data tracking and verification capabilities, combined with McKesson’s industry leading 3PL, specialty pharmacy solutions and patient support capabilities, are critical to helping manufacturers safely and effectively commercialize innovative new therapies. This integrated system will help prescribers and manufacturers work together seamlessly to ensure that the right patient always receives the correct therapeutic product at the right time.”

###

About TrakCel

TrakCel is the market-leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.

TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey. It aims to employ over 100 people by end of 2019, following a number of senior appointments in 2016 and 2017.

About McKesson Corporation

McKesson Corporation, currently ranked 7th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, healthcare technology, community oncology and specialty care. McKesson partners with life sciences companies, manufacturers, providers, pharmacies, governments and other healthcare organizations to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities to improve patient care in every setting — one product, one partner, one patient at a time. McKesson has been named a “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.

Press Release: TrakCel appoints senior director to expand US team

Expansion of US TrakCel team to match ongoing growth of cell and gene therapy customer base

Cardiff, UK, July 2nd, 2019 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, announces today the appointment of Maryellen Papelian as senior director of customer delivery.

“TrakCel’s software orchestration platforms are now an integral component throughout much of the international clinical development of the cell and gene therapy industry. As the sector continues to expand, and we work with a greater number of companies, it is critical that we in turn expand capabilities to support existing clients in key international regions. This includes further expansion of our US customer management,” said Ravi Nalliah, CEO, TrakCel. “We selected Maryellen Papelian as a specialist in the implementation of supply chain orchestration platforms at scale. She will provide the integral link between the specific requirements of the client and TrakCel’s software to ensure our individually tailored packages are adjusted on an ongoing basis to the evolving needs of the client.”

Maryellen brings to TrakCel over 20 years experience in large-scale IT roll-out implementations focusing on re-engineering business processes. In the last seven years, Maryellen has successfully set the IT infrastructure, and developed business processes for the successful rollout of solutions supporting a number of clinical to commercial product launches. These solutions range from legal, finance, quality, regulatory, clinical, HR, manufacturing, and supply chain. She additionally acquired extensive biotech experience as the director of enterprise applications at the genome editing company Editas Medicine, the gene therapy firm bluebird bio, the rare disease company Synageva, and Haemonetics, which provides blood management solutions. As a result, Maryellen provides TrakCel additional industry insight of project deliveries from both a client and supplier viewpoint.

Maryellen Papelian - TrakCel

Maryellen is TrakCel’s latest US senior appointment as the company expands its US management team. This is to ensure TrakCel continues to meet existing business requirements as the number of clients operating in the US continues to grow. This will enable TrakCel to continue to provide senior and highly qualified locally based support to cell and gene therapy client operations in both the EU and US.

“The cell and gene therapy industry continues to grow and evolve. This results in more complex supply chains with broader therapeutic indications and wider geographical clinical operations. These challenges mean the demand for implementation software will continue to increase,” said Maryellen Papelian, senior director of customer delivery, TrakCel. “I have been part of the selection and implementation of a variety of supply chain systems in my recent career. As a result, from that experience, I wanted to apply my technical, commercial and industry experience to TrakCel’s ethos and technical solutions. I feel this is the best option for me to contribute to life changing personalized medicines reaching the market and benefiting patients.”

About TrakCel

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.

TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.

TrakCel recognised as one of Wales’ Most Exciting Companies

Adding to a series of business awards in 2019, TrakCel is delighted to announce that it has been recognised as one of Wales’ Most Exciting companies.

Wales is home to a wealth of innovative, fast-moving companies that are setting the pace for industries in the UK and further afield. The annual awards are curated and shortlisted by Business Insider Wales with the aim of showcasing both emerging and established companies across a variety of sectors.

TrakCel has been recognised on the back of a highly successful start to 2019 that includes surpassing 100 staff; further expansion in the US with new client wins; and its CEO, Ravi Nalliah placing in the prestigious Medicine Maker Power List 2019.

Speaking of the award, Head of Talent and People, Joy Lewis-Middleton commented:

“TrakCel is delighted to be recognised as part of the Wales’ Most Exciting Companies by Business Insider Magazine. To be featured among some of Wales’ most innovative companies is a huge compliment and a reflection of our continued success. The company is continuing to draw talent from around the country to support its growth and award recognition such as this is a great attraction for candidates”.

Wales’ Most Exciting companies is curated each year by Business Insider Magazine. For more information on the awards click here.

 

 

Be The Match BioTherapies® and TrakCel partner to standardize cell and gene therapy supply chain solutions

Minneapolis, US and Cardiff, UK, June 18th, 2019Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and TrakCel, a software developer for cell and gene therapy supply chain tracking and orchestration systems, today announces a collaboration that will provide integrated solutions for companies developing cell and gene therapies.

This strategic partnership will enable cell and gene therapy developers to benefit from an integrated suite of industry-leading services and technology platforms. This combination of services and platforms has been designed to improve operations at every step of the cell and gene therapy supply chain. These steps range from clinical delivery to commercial-scale operations and coordination of these activities through a single software platform.

“Be The Match BioTherapies and TrakCel share the goal of ensuring that the next generation of cell and gene therapies can be developed efficiently and delivered to patients safely and reliably,” said Chris McClain, vice president, Sales and New Business Development, Be The Match BioTherapies. “This collaboration will allow us to develop the custom solutions best suited for each individual program and patient population.”

“Be The Match BioTherapies and TrakCel share the goal of ensuring that the next generation of cell and gene therapies can be developed efficiently and delivered to patients safely and reliably”

Be The Match BioTherapies and TrakCel will identify the unique challenges faced by cell and gene therapy developers and integrate services and platforms that provide direct solutions. Be The Match BioTherapies will contribute solutions for cell sourcing, cell therapy supply chain, clinical study design and execution, cellular therapy outcomes registry, and IT systems. TrakCel will provide its chain of custody/chain of identity (COC/COI), scheduling and logistics management software platform. The integration will increase efficiencies and eliminate redundancies while supporting all aspects of the supply chain in accordance with regulatory and protocol requirements. Both companies are already working together to deliver the integrated offering in support of a client’s CAR-T development program.

“Clinical and commercial advances in cell and gene therapies continue to progress dramatically. However, the resultant increases in complexity and stakeholders involved in the supply chain can leave it stretched and fragmented, potentially exposing patients to unnecessary risks,” said Ravi Nalliah, CEO, TrakCel. “As a result, TrakCel is continuing to sign partnerships with relevant industry providers to ensure the ever-growing supply chain can be effectively managed. This specific partnership with Be The Match BioTherapies will enable us to provide a more standardized and streamlined cell and gene therapy development process. That, in turn, will accelerate the delivery of vital new therapies to patients.”

Ends

Notes to editors

About TrakCel

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.

For more information, follow TrakCel on LinkedIn or Twitter at @TrakCel_

About Be The Match BioTherapies®

Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program®/Be The Match®, and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance cell and gene therapies in any stage of development.

Be The Match BioTherapies is dedicated to providing high-quality cellular starting material consented for research, clinical and commercial use, developing and managing expansive cell collection networks, and navigating cell therapy regulatory compliance. Using proven infrastructure to successfully manage cell therapy supply chains, including MatchSource® Supply Chain Software, dedicated cell therapy supply chain case managers and logistics experts, the organization has a history of compliance managing the chain of identity. The collaboration with CIBMTR extends services to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, follow Be The Match BioTherapies on LinkedIn or Twitter at @BTMBioTherapies.

 

 

TrakCel Chief Operating Officer awarded ‘International Director of the Year’

James Rudolf recognised at annual Welsh Institute of Directors Awards.  

The Chief Operating Officer of TrakCel is “extremely proud” to have been named as ‘International Director of the year’ at this year’s Welsh Institute of Directors Awards.  

James Rudolf, who has been with the TrakCel since 2016 was nominated in recognition of the company’s international impact, with an increasing number of personalised therapy companies across North America and Europe adopting TrakCel’s supply chain orchestration software.  

TrakCel has witnessed rapid growth over the last 12 months with business highlights including 300% growth, expansion into additional premises and surpassing 100 staff from its Cardiffbased offices.  

Speaking of the award, James commented: 

“I was delighted to pick up this award and honoured to be around so many inspirational directors..

“The last few years have been phenomenal in terms of business success and subsequent growth at TrakCel, but this success is down to the whole team. 

“We have huge aspirations to grow our business globally but in order to do so, we need to increase our workforce in Wales.   

“We’re proud of the fact that we are helping to bring truly life-changing products to the market through our innovative software, and we hope that others will be attracted to our story and our journey.”

James Rudolf Director of the Year

James Rudolf, TrakCel COO wins ‘International Director’ of the Year

Both Liam Fox, Secretary of State for International Trade & President of the Board of Trade and Secretary of State for Wales Alun Cairns attended the prestigious awards at Cardiff’s Sophia Gardens and recognised the success of inspiring and pioneering business leaders in Wales.  

Dr. Fox encouraged attendees to be optimistic about the future of Welsh businesses because of their underlying strengths and contribution to Wales’ bright trading future.   

The awards, now in their ninth year, have become an established highlight on the Welsh business calendar and celebrate business achievements and inspirational leaders across Wales while bringing all sectors of the business community together, irrespective of size, geography and longevity. 

Robert Lloyd Griffiths, Director IoD Wales said: “I am delighted that The Secretaries of State for International Trade and for Wales were able to support us at our awards celebration. Businesses across Wales are making huge efforts to contribute to the economy and our members continue to make a positive impact in Wales, the UK and on the global stage. The Institute of Directors (IoD) Wales Awards recognise the very best talent and achievements of Directors and we are confident that great Directors mean great businesses which ultimately means a better economy.

“Sincere thanks to all those who entered and sponsored this afternoon’s awards which were a celebration of exemplary leadership, which was showcased here to an incredible extent.”

Press Release – Cutting edge medical software company hits 100 employee mark

Press Release. Cardiff, Wales, UK.

Cardiff medical software company TrakCel will be increasing its headcount beyond 100 as it continues to expand its workforce to meet global demand for its product.

Having more than doubled its employee numbers during the financial year, the innovative software developer is set to recruit over 40 people in 2019.

The company’s recruitment drive comes off the back of 300% revenue growth in 2018.

To accommodate its growing team, the award-winning firm, which develops supply chain management software solutions for cell and gene therapy companies all over the world, has expanded into its third office in Cardiff city center.

Forecasting for further growth this year, the firm is recruiting various roles at its Cardiff headquarters, including Customer Support, Technical Business Analysts and Software Developers.

With offices in the UK and North America, TrakCel has witnessed rapid growth in the US over the last year with over 80% of its business now deriving from there. Consequently, the company is also looking to recruit two Directors of Customer Delivery in the US to further enhance service levels to its growing North American client base.

To facilitate its recruitment drive, TrakCel has brought in Head of People and Talent, Joy Lewis-Middleton. HR specialist Joy brings a wealth of experience having held senior roles at Target Group and Capital Law.

She said: “It’s an exciting time to be at TrakCel. We doubled in size last year and we are still growing. There are a number of roles we’re looking to fill across Software Development, Product Management, Testing, Business Analysis, Process Analysis and Project Management which we are confident of filling through local talent.

We’re extremely passionate about what we do and what we do matters. That’s one of the main reasons people are attracted to working for us. Not only can they pursue their career with us, but they can do so knowing they’re helping bring truly life-changing products to the market through our innovative software.”

TrakCel company growth

TrakCel CEO, Ravi Nalliah and Head of People & Talent, Joy Lewis-Middleton.

The growing field of personalized medicine is producing very promising treatments against a variety of cancers by utilizing a patient’s own cells to target and fight back against cancer. TrakCel was developed in 2012 to trace and streamline the complex supply chains associated with these personalized treatments. It has since gone on to experience a huge demand for its innovative software.

CEO and co-founder Ravi Nalliah, who recently retained his place in the distinguished Medicine Maker Power List 2019, said: “The last few years have been phenomenal in terms of business success and subsequent growth and we’re delighted to hit the 100-employee mark. We have huge aspirations to continue to grow our business globally and we need to increase our Wales-based workforce to facilitate this. It’s a pivotal time in our journey and we’re looking forward to welcoming more new people to the team over the course of the year.”

Established in 2012, TrakCel is an international technology company providing supply chain management software solutions to companies discovering, developing and commercializing cell and gene therapies and personalized medicine.

For more information on joining TrakCel, visit www.trakcel.com/careers

TrakCel CEO named in Medicine Maker Top 100 Power List 2019

Ravi Nalliah retains place in the distinguished Medicine Maker Power List.

Now in its 4th year, the annual Medicine Maker Power List awards celebrate the achievements of some of the most influential figures within the pharma industry. The awards recognize individuals across four categories: Masters of the Bench, Industry Influencers, Business Captains and Champions of Change, reflecting the great talent within the industry, from pioneering scientists to entrepreneurs and regulators.

This year’s List mirrors the ongoing evolution of the pharma industry, with the emergence of advanced therapies being reflected in a record number of places awarded to scientists and business people from the cell and gene space. The awards also feature a record number of nominees from Asia, including the first employee of a Chinese company – reflecting the increasing importance of China to the global industry.

After entering the Power List for the first time in 2018, Ravi Nalliah (TrakCel CEO) has successfully retained his position within the “Business Captains” category of the list in recognition of the growth and innovation demonstrated by TrakCel within the pharma industry.

Ravi Nalliah - TrakCel CEO

TrakCel CEO, Ravi Nalliah

Speaking of the award, Ravi Nalliah commented:

“I am honored to be featured on the ‘Medicine Maker Power List’ alongside some of the most pioneering scientists, regulators and thought leaders. Retaining my position in the 2019 Power List is testament to the commitment and innovation of my colleagues at TrakCel and our shared vision to support the delivery of life-changing advanced therapies”.

TrakCel is the market leading developer of clinical orchestration software designed to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining compliance and traceability.

More information about the Medicine Maker awards can be found here.

Government boost for expanding the use of cell and gene therapies in the UK

The SAMPLE programme (Standard Approach to atMP tissue colLEction), a vital programme to help build capacity for the NHS to expand the use of a new generation of cell and gene therapies for cancer and non-cancer illnesses has been given the green light by Innovate UK, the UK’s innovation agency.

An award made by Innovate UK, through the Industrial Strategy Challenge Fund is supporting the SAMPLE programme, a project to standardise the way cell and gene samples are collected to then be modified to become Advanced Therapy Medicinal Products (ATMPs).

The project will be led by a team of researchers from The Christie, part of the Manchester Cancer Research Centre. This team will be working with a nationwide consortium of NHS Trusts (Manchester University NHS Foundation Trust, Guy’s and St. Thomas’ NHS Foundation Trust, Newcastle upon Tyne), NHS Blood and Transplant and the Scottish National Blood Transfusion Service and industrial partners Asymptote, TrakCel, Immetacyte and Autolus. The Cell and Gene Therapy Catapult, a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK, will support the project in its role of coordinator of the Advanced Therapy Treatment Centre Network.

The number of patients to be treated with ATMPs is predicted to rise to 10,000 per annum over the next decade, from approximately 200 patients in 2018, which will require a doubling or tripling in sample processing capacity to support this level of activity. The SAMPLE programme will focus on developing a standardised approach to the collection of tissue and cell based starting materials essential to the manufacture of ATMPs by building on existing resources and capabilities.

The consortium will be investigating standardising cell and tissue procurement, processing and storage processes within the NHS.

Unlike conventional medicines, cell and gene therapies offer revolutionary treatments which repair, replace, regenerate and re-engineer genes, cells and tissues to restore normal function, sometimes offering potential cures where acute unmet medical need exists. Such treatments often manipulate the patient’s own cells to fight these diseases. However, new systems are needed to deliver these transformative therapies into the NHS.

This project is proactively addressing the organisational changes needed to address this increasing requirement for treatment with ATMPs. ATMPs have significant health economic and organisational implications which need to be proactively addressed to enable more life changing treatments to be provided to children and adults with cancer and non-cancer diseases.

Fiona Thistlethwaite, Medical Oncology consultant at The Christie and a SAMPLE project lead said “SAMPLE represents a fantastic opportunity to link UK partners from across the NHS and industry to establish standard practices in the complex but very exciting field of Advanced Therapies.”

Marc Turner, Medical Director at the Scottish National Blood Transfusion Service said: “Advanced Therapies have the potential to change the way we treat many common serious diseases including degenerative conditions and cancers.  SNBTS is delighted to be working with our commercial, academic and healthcare partners across the UK working to help realise this next generation of personal medicines.”

Dr Ian Campbell, Interim Executive Chair, Innovate UK for UKRI, said: “The project announced today will bring real benefits to patients and boost the knowledge economy as part of the government’s modern Industrial Strategy. This is vital for the UK as a global leader in the development of advanced therapies and medicine manufacturing.” Innovate UK has funded not only the SAMPLE study but the development of the Advanced Therapy Treatment Centres themselves.

This programme links together a national network of IUK funded Advanced Therapy Treatment Centres including iMATCH (Innovate Manchester Advanced Therapy Centre Hub), the Northern Alliance Advanced Therapies Treatment Centre (encompassing Newcastle, Leeds and Scotland) and the Midlands and Wales Advanced Therapies Treatment Centre (comprising Birmingham, Nottingham and Wales). Innovate UK has already committed to supporting Advanced Therapy Treatment Centres until 2021, to specialise in the delivery of cell and gene therapy products, for further information see https://www.theattcnetwork.co.uk/.

Notes for editors

The Christie

The Christie is the largest single-site cancer centre in Europe. As well as housing the largest early-phase clinical trials unit in the UK and one of the largest in Europe, it is also the first UK centre to be officially accredited as a comprehensive cancer centre.

Innovate UK:

Innovate UK is the UK’s innovation agency. We work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. Since 2007 we have invested over £1.5 billion in innovation, matched by a further £1.5 billion in partner and business funding. We have helped more than 5,000 innovative companies in projects estimated to add £7.5 billion to the UK economy and create 35,000 extra new jobs. https://www.gov.uk/government/organisations/innovate-uk

The Industrial Strategy Challenge Fund

The Industrial Strategy Challenge Fund is part of government’s Industrial Strategy, the long-term plan to raise productivity and earning power in the UK.

The fund is a core pillar in the government’s commitment to increase funding in research and development by £4.7 billion over 4 years to strengthen UK science and business.

It will invest in the world-leading research base and highly-innovative businesses to address the biggest industrial and societal challenges today.

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With over 180 experts focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.